P

    Profound Medical Corp (PROF)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $6.80
    -0.05 (-0.73%)

    Market Cap: $248.47M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -0.28%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.23
    Range$-0.25 - $-0.21
    4 analysts
    EPS RevisionsNo revisions (7d)
    1
    3
    30d
    EPS Estimate Drift
    90d ago$-0.23-2.2%
    60d ago$-0.24-6.6%
    30d ago$-0.24-6.6%
    7d ago$-0.24-6.6%
    Current$-0.23
    Revenue Consensus
    $10M
    Range$8M - $12M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.14
    Range$-0.17 - $-0.12
    4 analysts
    Revenue Consensus
    $13M
    Range$12M - $18M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.14---
    Sep 26EST
    		-$-0.23---
    Jun 26
    Reported Aug 6
    		$0.26$-0.22+218.18%Beat+150.0%
    Mar 26
    Reported May 7
    		$-0.19$-0.25+24.00%Beat+47.2%
    Dec 25
    Reported Mar 5
    		$-0.27$-0.30+10.60%Beat-35.0%
    Sep 25
    Reported Nov 13
    		$-0.26$-0.38+31.58%Beat+31.6%
    Jun 25
    Reported Aug 14
    		$-0.52$-0.40-30.00%Miss-85.7%
    Mar 25
    Reported May 8
    		$-0.36$-0.28-28.57%Miss-38.5%
    Dec 24
    Reported Mar 6
    		$-0.20$-0.32+37.98%Beat+52.4%
    Sep 24
    Reported Nov 7
    		$-0.38$-0.30-26.67%Miss-46.2%
    Jun 24
    Reported Aug 8
    		$-0.28$-0.28+0.00%Beat+20.0%
    Mar 24
    Reported May 9
    		$-0.26$-0.31+16.13%Beat+18.8%
    Dec 23
    Reported Mar 7
    		$-0.42$-0.32-31.25%Miss+8.7%
    Sep 23
    Reported Nov 2
    		$-0.26$-0.32+18.75%Beat-8.3%
    Jun 23
    Reported Aug 9
    		$-0.35$-0.34-2.94%Miss-25.0%
    Mar 23
    Reported May 10
    		$-0.32$-0.34+5.88%Beat+20.0%
    Dec 22
    Reported Mar 7
    		$-0.46$-0.36-27.78%Miss+6.1%
    Sep 22
    Reported Nov 3
    		$-0.24$-0.38+36.84%Beat+17.2%
    Jun 22
    Reported Aug 4
    		$-0.28$-0.39+28.21%Beat+20.0%
    Mar 22
    Reported May 9
    		$-0.40$-0.43+6.98%Beat-8.1%
    Dec 21
    Reported Mar 3
    		$-0.49$-0.37-32.43%Miss+0.0%
    Sep 21
    Reported Nov 4
    		$-0.29$-0.30+3.33%Beat+12.1%
    Jun 21
    Reported Aug 4
    		$-0.35$-0.30-16.67%Miss+0.0%
    Mar 21
    Reported May 12
    		$-0.37$-0.29-27.59%Miss-105.6%
    Dec 20
    Reported Mar 2
    		$-0.49$-0.43-13.95%Miss-52.6%
    Sep 20
    Reported Nov 5
    		$-0.33$-0.24-37.50%Miss+23.3%
    Jun 20
    Reported Aug 6
    		$-0.35$-0.21-66.67%Miss+7.9%
    Mar 20
    Reported May 7
    		$-0.18$-0.26+30.77%Beat+18.2%
    Dec 19
    Reported Mar 3
    		$-0.32$-0.49+34.80%Beat+35.8%
    Sep 19
    Reported Nov 7
    		$-0.43$-0.38-13.16%Miss-13.2%
    Jun 19
    Reported Aug 14
    		$-0.38$-0.33-15.15%Miss+0.0%
    Mar 19
    Reported May 6
    		$-0.22$-0.33+33.33%Beat+53.2%
    Dec 18
    Reported Mar 7
    		$-0.50$-0.45-11.11%Miss+16.7%
    Sep 18
    Reported Nov 8
    		$-0.38$-0.34-11.76%Miss+45.7%
    Jun 18
    Reported Aug 14
    		$-0.38$-0.29-31.03%Miss-375.0%
    Mar 18
    Reported May 10
    		$-0.47$-0.31-51.61%Miss+7.8%
    Dec 17
    Reported Mar 26
    		$-0.60$-0.50-20.00%Miss-757.1%
    Sep 17
    Reported Nov 7
    		$-0.70$-0.56-25.00%Miss+6.7%
    Jun 17
    Reported Aug 23
    		$-0.08$-0.07-14.29%Miss-
    Mar 17
    Reported May 9
    		$-0.51$-0.52+1.92%Beat-
    Dec 16
    Reported Mar 6
    		$-0.07$-0.07+0.00%Beat-
    Sep 16
    Reported Nov 16
    		$-0.75$-0.65-15.38%Miss-

    Key Metrics

    Valuation
    P/E Ratio-14.78EV/EBITDA-5.75x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-171.60%Operating Margin-445.70%
    ROE-73.50%ROIC-61.70%
    Financial Health
    Debt/Equity0.09xInterest CoverageN/A
    Current Ratio6.46xQuick Ratio5.31x
    Trading Statistics
    Beta0.53Avg Volume114.54K
    52-Week High$8.9552-Week Low$3.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.88
    SMA 20$7.08
    SMA 50$7.04
    SMA 200$6.90
    EMA 10$6.90
    EMA 20$6.98
    EMA 50$7.00
    EMA 200$6.75

    MACD

    Line: -0.09Signal: -0.07Hist: -0.02

    ADX

    ADX: 15.7+DI: 22.9-DI: 19.3

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down60.0
    PSAR$6.56

    Bollinger Bands

    Upper Band$8.07
    Lower Band$6.09
    %B Position2791%(Upper)
    Band Width0.36

    RSI (14-Day)

    Neutral
    45.3

    Momentum Oscillators

    Stoch %K36.1
    Stoch %D38.6
    Williams %R-67.8
    ROC (10d)3.8%
    Momentum0.25
    CCI (20d)-54.0
    MFI (14d)53.3

    Volatility Measures

    ATR (14d)$0.39(5.8%)
    StdDev (20d)0.49
    Hist Vol52.6%(High)

    Volume Flow

    VWAP$6.84
    OBV-607.9K
    AD Line-3.3K
    CMF (20d)-0.238

    Volume Metrics

    Avg Vol (20d)109.0K
    Vol Ratio0.6x
    VWMA (20d)$7.09

    Pivot Points

    R3$7.04
    R2$6.99
    R1$6.92
    Pivot Point$6.87
    S1$6.80
    S2$6.75
    S3$6.68

    Advanced Oscillators

    TSI-6.81
    Ultimate Osc38.6
    KST-48.30

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.48M$5.34M$5.98M$5.29M$2.21M$2.62M$4.18M$2.83M$2.23M$1.44M$2.66M$1.73M
    Cost of Revenue$536,000$1.50M$1.99M$1.36M$593,000$768,000$1.21M$1.04M$812,000$573,000$1.35M$668,000
    Gross Profit$1.95M$3.83M$3.99M$3.93M$1.62M$1.85M$2.96M$1.79M$1.42M$866,000$1.31M$1.06M
    Operating Expenses$13.01M$11.85M$11.36M$12.84M$15.42M$13.02M$11.31M$10.79M$9.26M$8.74M$65.55M$7.62M
    R&D$5.65M$5.26M$4.27M$5.42M$6.10M$4.81M$4.65M$4.17M$4.21M$3.94M$5.32M$3.42M
    SG&A$7.36M$6.59M$7.09M$7.43M$9.33M$8.21M$6.66M$6.62M$5.06M$4.80M$8.23M$2.02M
    Operating Income$-11,066,000$-8,021,000$-7,369,000$-8,913,000$-13,806,000$-11,166,000$-8,345,000$-8,998,000$-7,842,000$-7,877,000$-64,241,170$-6,560,000
    Interest Income$336,000$377,000$160,000$122,000$343,000$445,000$332,000$220,000$422,000$462,000$1.37M$1.01M
    Interest Expense$0$0$779,000$0$1.82M$0$0$190,000$0$0$343,231$195,411
    Income Before Tax$-9,485,000$-7,028,000$-8,148,000$-7,856,000$-15,631,000$-10,683,000$-5,185,000$-9,188,000$-6,900,000$-6,545,000$-11,781,633$-5,546,000
    Income Tax Expense$55,000$25,000$26,000$121,000$64,000$41,000$-238,000$177,000$19,000$40,000$-303,418$18,000
    Net Income$-9,540,000$-7,053,000$-8,174,000$-7,977,000$-15,695,000$-10,724,000$-4,947,000$-9,365,000$-6,919,000$-6,585,000$-11,478,215$-5,564,000
    EBITDA$-9,686,000$-7,305,000$-8,199,000$-7,831,000$-15,833,000$-10,965,000$-5,279,000$-9,194,000$-7,088,000$-6,757,000$-11,357,642$-6,273,000
    EBIT$-9,821,000$-7,405,000$-8,308,000$-7,978,000$-15,974,000$-11,128,000$-5,517,000$-9,408,000$-7,322,000$-7,007,000$-11,682,260$-6,560,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PROF

    News

    Profound Medical Names Industry Veteran Richard Fabian as President in Leadership Realignment

    Profound Medical has appointed Richard Fabian, an industry veteran in medical imaging and devices, as its new President. Former President Mathieu Burtnyk will transition to Chief Technology Officer. This leadership realignment aims to enhance commercial execution and global market expansion for Profound's MRI-guided, AI-driven incisionless therapies, particularly its TULSA-PRO technology.

    TipRanks•9/1/26•
    Neutral

    Profound Medical Stock Falls 2.63%: Can TSX:PRN Overcome Commercialization Challenges and Healthcare Technology Risks?

    Profound Medical (TSX:PRN) shares recently dropped 2.63% due to investor caution regarding the company's commercialization progress and financial sustainability. The company, which develops MRI-guided therapeutic technologies like TULSA-PRO for prostate disease, faces challenges in hospital adoption, reimbursement, and achieving consistent profitability despite improving revenue trends. Its long-term success hinges on broader market acceptance of its minimally invasive solutions and effective execution of its commercial strategy.

    kalkine.ca•8/28/26•
    Neutral

    Profound Medical Corp. Stock Surges 4.46% as Trading Activity Spikes and Market Attention Builds

    Profound Medical Corp. (TSX:PRN) shares jumped 4.46% on August 26, 2026, driven by a surge in trading activity and investor interest. The specific catalyst for this sharp increase has not been independently confirmed through company disclosures. Profound Medical is a medical technology company specializing in MRI-guided, incision-free ablation therapy platforms, including its TULSA-PRO system for prostate tissue therapy.

    kalkine.ca•8/26/26•
    Somewhat-Bullish

    Form 8K PROFOUND MEDICAL CORP. For: 17 August By Investing.com

    This article announces that PROFOUND MEDICAL CORP. filed a Form 8K on August 17. The brief report from Investing.com is solely an informational notice about the regulatory filing. No further details about the content of the 8K are provided.

    Investing.com Nigeria•8/17/26•
    Neutral

    Profound Medical (TSE:PRN) Insider Thomas Michael Tamberrino Buys 3,755 Shares of Stock

    Profound Medical insider Thomas Michael Tamberrino recently purchased 3,755 shares of the company's stock for C$9.44 per share, increasing his total ownership by 7.54% to 53,573 shares. This insider buying comes as the company reported weak financial results, including a quarterly loss of C$0.37 per share and a negative net margin of 170.92%. Despite the stock's recent drop and financial challenges, analysts maintain a "Moderate Buy" consensus, with Raymond James upgrading their rating to "strong buy."

    MarketBeat•8/17/26•
    Neutral

    Frequently Asked Questions About PROF

    Does PROF pay dividends?
    Profound Medical Corp (PROF) does not currently pay a regular dividend.
    What is PROF's market cap?
    Profound Medical Corp (PROF) has a market capitalization of $248.47M with a current stock price of $6.80.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In